Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-04-22
    E.g., 2018-04-22

Articles

Pages

19243 items
6:28 PM, Apr 20, 2018  |  BioCentury | Product Development

Redrawing the lines

Word that Merck & Co. Inc.’s Keytruda pembrolizumab had “won” the first-line lung cancer showdown with Bristol-Myers Squibb Co. at AACR spread quickly on Monday, but there was little discussion among investors and in the...
5:44 PM, Apr 20, 2018  |  BioCentury | Finance

Takeda’s math problem

A hefty net debt load of $18.8 billion for Shire plc (LSE:SHP; NASDAQ:SHPG) means Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) is having to pick its poison to reach a deal. The Japanese pharma is grappling with giving...
5:16 PM, Apr 20, 2018  |  BioCentury | Finance

Qiming’s cross-border connection

Qiming Venture Partners chose to focus its first ex-China fund on healthcare because the firm sees more interest in cross-border collaborations in life sciences than some of the other industries it invests in. Qiming unveiled...
5:01 PM, Apr 20, 2018  |  BioCentury | Finance

China’s early stage Panacea

Despite a recent wave of large funds investing in Chinese biotechs, new Chinese VC Panacea Venture believes a pair of funds totaling roughly $300 million is more than enough to pursue its early stage investing...
4:45 PM, Apr 20, 2018  |  BioCentury | Product Development

Lessons from the ECHO chamber

Lessons from the failure of ECHO-301 go beyond the prospects of combining IDO1 and PD-1 inhibition to treat cancer. The broader concern is for the gamut of Phase I/II trials testing PD-1 combinations, many of...
3:56 PM, Apr 20, 2018  |  BioCentury | Emerging Company Profile

Clear for Landos

Landos Biopharma Inc. is developing a first-in-class LANCL2 agonist designed to provide improved convenience, efficacy and safety over standard-of-care therapies for inflammatory bowel disease (IBD), including moderate to severe Crohn’s disease (CD) and ulcerative colitis...
3:04 PM, Apr 20, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least 17 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in London; premarket on U.S. exchange; (B) Fiscal 4Q; (C) 12-month EPS. CompanyDatePre/post mkt1Q18 EPS est1Q17...
10:39 AM, Apr 20, 2018  |  BioCentury | Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
4:29 PM, Apr 13, 2018  |  BioCentury | Tools & Techniques

Personalizing prevention

PlaqueTec Ltd. is working to bring personalized medicine to the cardiovascular space with a device that samples local concentrations of molecules near atherosclerotic plaques. By using these samples to identify prognostic and predictive biomarkers, the...
3:25 PM, Apr 13, 2018  |  BioCentury | Emerging Company Profile

Reversing Neuropathy

Regenacy Pharmaceuticals LLC is developing the selective histone deacetylase 6 inhibitor ricolinostat as the first disease-modifying therapy for chemotherapy-induced peripheral neuropathy and diabetic neuropathy. Regenacy was spun out of Acetylon Pharmaceuticals Inc. during its 2016...

Pages